by | Sep 2, 2026 | Uncategorized
Alumis says envudeucitinib failed its primary endpoint in a 408-patient lupus trial but plans Phase 3 in a subgroup. Why that carries risk.
by | Sep 2, 2026 | Uncategorized
Arlington sprayed for West Nile over two September nights after one trap tested positive. Here is what triggers spraying and what residents should do.
by | Sep 2, 2026 | Uncategorized
The FDA added a PFAS FAQ for medical devices on Sept. 1, explaining why fluoropolymers in catheters and stents differ from PFAS in drinking water.
by | Sep 2, 2026 | Uncategorized
Two Phase 3 trials of plozasiran cut triglycerides by about 80% and reduced acute pancreatitis events by 78%. An FDA filing is expected by year-end.
by | Sep 2, 2026 | Uncategorized
FDA added a boxed warning to Injectafer over symptomatic hypophosphatemia. Fewer than 20% of infusions include a blood test that would catch it.
Recent Comments